Alterity Therapeutics Limited (NASDAQ:ATHE) Sees Significant Increase in Short Interest

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 167,300 shares, a growth of 12.6% from the December 31st total of 148,600 shares. Based on an average daily volume of 64,600 shares, the short-interest ratio is presently 2.6 days. Approximately 2.0% of the company’s shares are sold short.

Alterity Therapeutics Price Performance

ATHE stock traded up $0.23 during mid-day trading on Friday, reaching $4.80. The company had a trading volume of 791,484 shares, compared to its average volume of 80,638. Alterity Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $5.87. The firm has a fifty day simple moving average of $2.78 and a 200 day simple moving average of $1.83.

Institutional Trading of Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. HB Wealth Management LLC grew its position in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,883 shares of the company’s stock after acquiring an additional 8,100 shares during the quarter. HB Wealth Management LLC owned about 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Analysts Set New Price Targets

Separately, Maxim Group lifted their price objective on Alterity Therapeutics from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.